A Review of Antimicrobial Peptides and Their Therapeutic Potential As Anti-infective Drugs

Overview

Journal Curr Eye Res

Publisher Informa Healthcare

Specialty Ophthalmology

Date 2005 Jul 16

PMID 16020284

Citations 227

Authors

Y Jerold Gordon

Eric G Romanowski

Alison M McDermott

Affiliations

Soon will be listed here.

Abstract

Purpose: Antimicrobial peptides (AMPs) are an essential part of innate immunity that evolved in most living organisms over 2.6 billion years to combat microbial challenge. These small cationic peptides are multifunctional as effectors of innate immunity on skin and mucosal surfaces and have demonstrated direct antimicrobial activity against various bacteria, viruses, fungi, and parasites. This review summarizes their progress to date as commercial antimicrobial drugs for topical and systemic indications.

Methods: Literature review.

Results: Despite numerous clinical trials, no modified AMP has obtained Food & Drug Administration approval yet for any topical or systemic medical indications.

Conclusions: While AMPs are recognized as essential components of natural host innate immunity against microbial challenge, their usefulness as a new class of antimicrobial drugs still remains to be proven.

Citing Articles

Antimicrobial and antioxidant activities of peptide derived from turmeric plant (Curcuma longa L).

Roytrakul S, Charoenlappanit S, Kittisenachai S, Siangpro N, Sichaem J, Chuakrut S PLoS One. 2024; 19(11):e0314482.

PMID: 39585886 PMC: 11588247. DOI: 10.1371/journal.pone.0314482.

Exploring Tryptophan-based Short Peptides: Promising Candidate for Anticancer and Antimicrobial Therapies.

Rai N, Tiwari R, Sahu A, Verma E, Rathore S, Patil S Anticancer Agents Med Chem. 2024; 25(2):124-133.

PMID: 39297455 DOI: 10.2174/0118715206260662240613054521.

Semantic search using protein large language models detects class II microcins in bacterial genomes.

Kulikova A, Parker J, Davies B, Wilke C mSystems. 2024; 9(10):e0104424.

PMID: 39291976 PMC: 11494933. DOI: 10.1128/msystems.01044-24.

Oral microbiota and metabolites: key players in oral health and disorder, and microbiota-based therapies.

Bostanghadiri N, Kouhzad M, Taki E, Elahi Z, Khoshbayan A, Navidifar T Front Microbiol. 2024; 15:1431785.

PMID: 39228377 PMC: 11368800. DOI: 10.3389/fmicb.2024.1431785.

Synergistic action of antimicrobial peptides and antibiotics: current understanding and future directions.

Taheri-Araghi S Front Microbiol. 2024; 15:1390765.

PMID: 39144233 PMC: 11322369. DOI: 10.3389/fmicb.2024.1390765.

References

Narayanan S, Miller W, McDermott A . Expression of human beta-defensins in conjunctival epithelium: relevance to dry eye disease. Invest Ophthalmol Vis Sci. 2003; 44(9):3795-801. PMC: 1497873. DOI: 10.1167/iovs.02-1301. View

Ganz T . Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003; 3(9):710-20. DOI: 10.1038/nri1180. View

Kowalski R, Dhaliwal D, Karenchak L, Romanowski E, Mah F, Ritterband D . Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003; 136(3):500-5. DOI: 10.1016/s0002-9394(03)00294-0. View

Maisetta G, Batoni G, Esin S, Luperini F, Pardini M, Bottai D . Activity of human beta-defensin 3 alone or combined with other antimicrobial agents against oral bacteria. Antimicrob Agents Chemother. 2003; 47(10):3349-51. PMC: 201125. DOI: 10.1128/AAC.47.10.3349-3351.2003. View

Quinones-Mateu M, Lederman M, Feng Z, Chakraborty B, Weber J, Rangel H . Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS. 2003; 17(16):F39-48. DOI: 10.1097/00002030-200311070-00001. View

Brogden K, Ackermann M, McCray Jr P, Tack B . Antimicrobial peptides in animals and their role in host defences. Int J Antimicrob Agents. 2003; 22(5):465-78. DOI: 10.1016/s0924-8579(03)00180-8. View

Beutler B . Innate immunity: an overview. Mol Immunol. 2003; 40(12):845-59. DOI: 10.1016/j.molimm.2003.10.005. View

Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R . A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys. 2004; 58(3):674-81. DOI: 10.1016/S0360-3016(03)01627-4. View

Kavanagh K, Dowd S . Histatins: antimicrobial peptides with therapeutic potential. J Pharm Pharmacol. 2004; 56(3):285-9. DOI: 10.1211/0022357022971. View

10.

Yang D, Biragyn A, Hoover D, Lubkowski J, Oppenheim J . Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol. 2004; 22:181-215. DOI: 10.1146/annurev.immunol.22.012703.104603. View

11.

Andres E, Dimarcq J . Cationic antimicrobial peptides: update of clinical development. J Intern Med. 2004; 255(4):519-20. DOI: 10.1046/j.1365-2796.2003.01278.x. View

12.

Tan H . Topical antibacterial treatments for acne vulgaris : comparative review and guide to selection. Am J Clin Dermatol. 2004; 5(2):79-84. DOI: 10.2165/00128071-200405020-00002. View

13.

Yasin B, Wang W, Pang M, Cheshenko N, Hong T, Waring A . Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J Virol. 2004; 78(10):5147-56. PMC: 400355. DOI: 10.1128/jvi.78.10.5147-5156.2004. View

14.

Giles F, Rodriguez R, Weisdorf D, Wingard J, Martin P, Fleming T . A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leuk Res. 2004; 28(6):559-65. DOI: 10.1016/j.leukres.2003.10.021. View

15.

De Clercq E . Antiviral drugs in current clinical use. J Clin Virol. 2004; 30(2):115-33. DOI: 10.1016/j.jcv.2004.02.009. View

16.

Yount N, Yeaman M . Multidimensional signatures in antimicrobial peptides. Proc Natl Acad Sci U S A. 2004; 101(19):7363-8. PMC: 409924. DOI: 10.1073/pnas.0401567101. View

17.

Finlay B, Hancock R . Can innate immunity be enhanced to treat microbial infections?. Nat Rev Microbiol. 2004; 2(6):497-504. DOI: 10.1038/nrmicro908. View

18.

Wang W, Owen S, Rudolph D, Cole A, Hong T, Waring A . Activity of alpha- and theta-defensins against primary isolates of HIV-1. J Immunol. 2004; 173(1):515-20. DOI: 10.4049/jimmunol.173.1.515. View

19.

Kowalski R, Romanowski E, Mah F, Yates K, Gordon Y . Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model. Am J Ophthalmol. 2004; 138(1):33-7. DOI: 10.1016/j.ajo.2004.02.051. View

20.

Sader H, Fedler K, Rennie R, Stevens S, Jones R . Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity. Antimicrob Agents Chemother. 2004; 48(8):3112-8. PMC: 478492. DOI: 10.1128/AAC.48.8.3112-3118.2004. View